Weight Loss

Online pharmacies, drug wholesalers under scanner; non-compliance may lead penalties, license cancellations

Experts highlight the limits of calorie tracking and share practical, sustainable ways for long-term weight management

India's 'cheap Ozempic moment' is here as semaglutide prices fall sharply, but doctors warn against misuse and stress careful evaluation before using these weight-loss injections

As cheaper GLP-1 weight-loss drugs flood India after patent expiry, the government has intensified surveillance to curb illegal sales, misleading promotion, and unsafe use without medical supervision

To ensure ethical pharmaceutical practices in the supply chain of weight-loss drugs of the GLP-1 class, the Drugs Controller General of India (DCGI) has intensified its regulatory surveillance against the unauthorised sale and promotion of the medications. To this end, inspections and audits have been carried out at many online pharmacy warehouses, drug wholesalers and retailers to check for unauthorised sale and improper prescription. With the recent introduction of multiple generic variants of GLP-1-based weight-loss drugs in the Indian market, concerns have emerged regarding their on-demand availability through retail pharmacies, online platforms, wholesalers, and wellness clinics, health ministry officials said on Tuesday. These drugs, when used without proper medical supervision, may lead to serious adverse effects and related health risks. Taking cognisance of the situation, the DCGI, in collaboration with state regulators, has initiated a series of targeted actions to curb .

Companies including Dr. Reddy's Laboratories, Sun Pharma, Zydus Lifesciences, Natco Pharma, Alkem Laboratories, and Torrent Pharmaceuticals have developed their own formulations

As semaglutide goes off patent, doctors warn of misuse by non-obese individuals amid rising demand driven by social media and lower-cost generics

Natco Pharma Ltd. plans to sell an injection for semaglutide, the active ingredient in both Ozempic and Wegovy - with prices starting from ₹1,290

India is the first major country after Canada where Novo is losing patent on semaglutide and will see an onslaught of generic versions

India is the first major country after Canada where Novo is losing patent on semaglutide and will see an onslaught of generic versions

Body weight is biologically regulated, and targeting the right biological pathways can lead to meaningful weight loss that can help transform lives

Originally developed for Type 2 diabetes, GLP-1 drugs like Ozempic and Wegovy prolong natural satiety signals, extending the post-meal fullness phase to support appetite control and weight loss

As Ozempic and other GLP-1 drugs gain popularity, experts explain who qualifies, the real health benefits, potential risks, side effects, and why supervision is critical

The tennis legend says she lost 15 kg using a GLP-1 medication after struggling with post-pregnancy weight, revealing the journey in a Super Bowl 2026 ad for telehealth firm Ro

Experts explain how under-eating, skipped meals, hormonal imbalance, stress and metabolic slowdown can push the body into survival mode and make losing weight harder over time

US biotech firm Fractyl Health is developing Rejuva, an experimental gene therapy that aims to trigger long-term weight loss by programming the pancreas to produce more GLP-1 hormone

Endocrinologist explains how to build a realistic weight-loss plan that can help you lose fat without regaining it

Eggs are praised as a protein powerhouse but blamed for cholesterol. A gastroenterologist answers common questions people still ask about weight loss, liver health, and daily egg intake

Many people regain weight after stopping Ozempic and similar drugs. Expert shares why it happens and the practical steps needed to maintain weight in the long term

Promoted as a natural shortcut to fat loss, liposomal berberine is drawing caution from doctors over safety, drug interactions and misleading comparisons with Ozempic